We expect that a more detailed understanding of the mechanism of action of RNR inhibitors will improve the clinical use and efficacy of this class of drugs, as single agents and in combination therapies, in Ewing sarcoma and other cancers. This evidence concerns the gene NR2E3 and Ewing sarcoma.